News
CODX
--
0.00%
--
Co-Diagnostics, Inc. to Present at ACTC Liquid Biopsy Conference in Kalamata, Greece
/PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company representatives will be presenting at t...
PR Newswire - PRF · 1d ago
BRIEF-Co-Diagnostics' Logix Smart Influenza A/Influenza B/Covid-19 "ABC" Test Has Been Approved For Sale In Mexico
reuters.com · 1d ago
BRIEF-Co-Diagnostics Inc Says Its Logix Smart Influenza A/Influenza B/Covid-19 "Abc" Test Has Been Approved For Sale In Mexico
reuters.com · 1d ago
Co-Diagnostics Reports Its Logix Smart Flu A/B/COVID-19 Test Approved For Sale In Mexico
Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ Influenza A/Influenza B/COVID-19
Benzinga · 1d ago
Co-Diagnostics, Inc. Logix Smart™ ABC Test Authorized for Use in Mexico
/PRNewswire/ -- Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ Influenza A/Influenza B/COVID-19 "ABC" Test has been approved for sale in ...
PR Newswire - PRF · 1d ago
Sidoti Fall Virtual Small Cap Investor Conference
ACCESSWIRE · 2d ago
Co-Diagnostics Gets Mexican Department of Epidemiology's Approval For Sale of Logix Smart Flu/COVID-19 Test in Mexico
MT Newswires · 2d ago
Co-Diagnostics To Present At Sidoti Virtual Investor Conference Thursday, Sept. 23, 2021 At 3:15 p.m. EDT
Co-Diagnostics, Inc. (NASDAQ:CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew
Benzinga · 2d ago
Co-Diagnostics, Inc. to Present at Sidoti Virtual Investor Conference
Co-Diagnostics, Inc. (NASDAQ: CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson, Head of Investor Relations, ...
PR Newswire · 2d ago
BRIEF-Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for Chikungunya and Dengue Tests
reuters.com · 6d ago
Demand Continues to Grow for Crucial Medical Supplies
/PRNewswire/ -- The emergence of the pandemic has helped accelerate the growth of demand for diagnostic supplies such as ventilators, N95 masks, and PPE kits, which in turn is fueling the medical supplies market growth. The hospital medical equipment and s...
PR Newswire - PRF · 6d ago
Co-Diagnostics Joint Venture Secures India Clearance for Chikungunya, Dengue Tests
MT Newswires · 09/16 10:11
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most lik...
Benzinga · 09/13 14:27
Co-Diagnostics, Inc. CEO to Participate in Panel Discussion with Scott Gottlieb, M.D., at H.C. Wainwright 2021 Annual Global Investor Conference
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate in a panel discussion ...
PR Newswire · 09/13 10:30
Co-Diagnostics SARS-CoV-2 Test Used In New Community Surveillance Method In Italy
o-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit was used by
Benzinga · 09/08 13:35
3 Magic Formula Stock Picks
GuruFocus News · 08/26 14:03
Co-Diagnostics, Inc. To Present At 13th Next Generation Dx Summit In Washington, D.C.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting and hosting a booth this week at the 13th...
PR Newswire · 08/23 13:30
New COVID-19 Vaccination Mandates Make Rapid COVID Tests More Essential Than Ever
/PRNewswire/ -- With the number of new COVID cases surging, fueled by a highly contagious Delta variant and only 50% of the US population having been vaccinated, the need for rapid testing and treatments is more important than ever. Perhaps even more alarm...
PR Newswire - PRF · 08/19 12:50
CoDiagnostics, Inc. (CODX) Just Reclaimed the 20-Day Moving Average
Zacks.com · 08/16 14:00
Co-Diagnostics, Inc. (NASDAQ:CODX) Surges 42% Yet Its Low P/E Is No Reason For Excitement
Co-Diagnostics, Inc. ( NASDAQ:CODX ) shares have had a really impressive month, gaining 42% after a shaky period...
Simply Wall St. · 08/14 07:19
Webull provides a variety of real-time CODX stock news. You can receive the latest news about Co-Diagnostics through multiple platforms. This information may help you make smarter investment decisions.
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.